Progression of Behavioral and CNS Deficits in a Viable Murine Model of Chronic Neuronopathic Gaucher Disease.

Progression of Behavioral and CNS Deficits in a Viable Murine Model of Chronic Neuronopathic Gaucher Disease.

To study the neuronal deficits in neuronopathic Gaucher Disease (nGD), the chronological behavioral profiles and the age of onset of brain abnormalities were characterized in a chronic nGD mouse model (9V/null). Progressive accumulation of glucosylceramide (GC) and glucosylsphingosine (GS) in the br...

Full description

Bibliographic Details
Main Authors:	Mei Dai, Benjamin Liou, Brittany Swope, Xiaohong Wang, Wujuan Zhang, Venette Inskeep, Gregory A Grabowski, Ying Sun, Dao Pan
Format:	Article
Language:	English
Published:	Public Library of Science (PLoS) 2016-01-01
Series:	PLoS ONE
Online Access:	http://europepmc.org/articles/PMC5012639?pdf=render

Similar Items

Isofagomine in vivo effects in a neuronopathic Gaucher disease mouse.
by: Ying Sun, et al.
Published: (2011-04-01)

Systemic enzyme delivery by blood-brain barrier-penetrating SapC-DOPS nanovesicles for treatment of neuronopathic Gaucher disease
by: Ying Sun, et al.
Published: (2020-05-01)

Viable neuronopathic Gaucher disease model in Medaka (Oryzias latipes) displays axonal accumulation of alpha-synuclein.
by: Norihito Uemura, et al.
Published: (2015-04-01)

Viable neuronopathic Gaucher disease model in medaka (Oryzias latipes) displays axonal accumulation of alpha-synuclein
by: Uemura, Norihito
Published: (2015)

Developing markers of neurological manifestations in Neuronopathic Gaucher Disease
by: Davies, E. H.
Published: (2011)

Intravenously administered gene therapy for neuronopathic Gaucher disease
by: Massaro, Giulia
Published: (2018)

Enhanced calcium release in the acute neuronopathic form of Gaucher disease
by: Dori Pelled, et al.
Published: (2005-02-01)

Identification of a biomarker in cerebrospinal fluid for neuronopathic forms of Gaucher disease.
by: Hila Zigdon, et al.
Published: (2015-01-01)

Successful therapy for protein-losing enteropathy caused by chronic neuronopathic Gaucher disease
by: A.A. Mhanni, et al.
Published: (2016-03-01)

Glycosphingolipid analysis in a naturally occurring ovine model of acute neuronopathic Gaucher disease
by: Litsa Karageorgos, et al.
Published: (2016-07-01)

Impact of Gba2 on neuronopathic Gaucher’s disease and α-synuclein accumulation in medaka (Oryzias latipes)
by: Etsuro Nakanishi, et al.
Published: (2021-05-01)

Innate immune response in neuronopathic forms of Gaucher disease confers resistance against viral-induced encephalitis
by: Sharon Melamed, et al.
Published: (2020-08-01)

Imaging of non-neuronopathic Gaucher disease: recent advances in quantitative imaging and comprehensive assessment of disease involvement
by: Andrew J. Degnan, et al.
Published: (2019-07-01)

Neuronopathic Gaucher disease : the pathobiological effects of glucosylsphingosine upon cellular actin within the central nervous system
by: Smith, Nicholas James Chapman
Published: (2014)

Substrate Reduction Therapy Reverses Mitochondrial, mTOR, and Autophagy Alterations in a Cell Model of Gaucher Disease
by: Yanyan Peng, et al.
Published: (2021-09-01)

In vitro and in vivo effects of Ambroxol chaperone therapy in two Italian patients affected by neuronopathic Gaucher disease and epilepsy
by: Giovanni Ciana, et al.
Published: (2020-12-01)

Viral delivery of a microRNA to Gba to the mouse central nervous system models neuronopathic Gaucher disease
by: Kasey L. Jackson, et al.
Published: (2019-10-01)

The GBA p.G85E mutation in Korean patients with non-neuronopathic Gaucher disease: founder and neuroprotective effects
by: Yoo-Mi Kim, et al.
Published: (2020-11-01)

Elevated Dkk1 Mediates Downregulation of the Canonical Wnt Pathway and Lysosomal Loss in an iPSC Model of Neuronopathic Gaucher Disease
by: Manasa P. Srikanth, et al.
Published: (2020-12-01)

<i>Drosophila melanogaster</i> Mutated in its <i>GBA1b</i> Ortholog Recapitulates Neuronopathic Gaucher Disease
by: Or Cabasso, et al.
Published: (2019-09-01)

Neurobehavioral phenotypes of neuronopathic mucopolysaccharidoses
by: Rita Barone, et al.
Published: (2018-11-01)

Substrate compositional variation with tissue/region and Gba1 mutations in mouse models--implications for Gaucher disease.
by: Ying Sun, et al.
Published: (2013-01-01)

Ubiquitous transgene expression of the glucosylceramide-synthesizing enzyme accelerates glucosylceramide accumulation and storage cells in a Gaucher disease mouse model.
by: Sonya Barnes, et al.
Published: (2014-01-01)

Semi-preparative expression and purification of a recombinant glucocerebrosidase protein with a PTD4 transduction domain: a potential therapeutic strategy for neuronopathic Gaucher’s disease.
by: Jack, Alexandria Taylor
Published: (2012)

Neuronopathic Types of Mucopolysaccharidoses: Pathogenesis and Emerging Treatments
by: L. A. Osipova, et al.
Published: (2015-11-01)

Investigating the neurobehavioral symptoms of neuronopathic Hunter syndrome
by: Nathan Grant
Published: (2020-03-01)

Gene Therapy for Neuronopathic Mucopolysaccharidoses: State of the Art
by: María José de Castro, et al.
Published: (2021-08-01)

Global gene expression profile progression in Gaucher disease mouse models
by: Zhang Wujuan, et al.
Published: (2011-01-01)

Prevalence and management of Gaucher disease
by: Burrow TA, et al.
Published: (2011-06-01)

Response to: Investigating the neurobehavioral symptoms of neuronopathic Hunter syndrome
by: J.B. Eisengart, et al.
Published: (2020-03-01)

The nature and impact of neurobehavioral symptoms in neuronopathic Hunter syndrome
by: J.B. Eisengart, et al.
Published: (2020-03-01)

The saccadic and neurological deficits in type 3 Gaucher disease.
by: William Benko, et al.
Published: (2011-01-01)

Elevated LysoGb3 Concentration in the Neuronopathic Forms of Mucopolysaccharidoses
by: Galina Baydakova, et al.
Published: (2020-03-01)

Modeling neuronopathic storage diseases with patient-derived culture systems
by: Friederike Zunke, et al.
Published: (2019-07-01)

Properties of neurons derived from induced pluripotent stem cells of Gaucher disease type 2 patient fibroblasts: potential role in neuropathology.
by: Ying Sun, et al.
Published: (2015-01-01)

Mutation analysis of gaucher patients in Taiwan
by: Li, Zheng Dao, et al.
Published: (1994)

In vivo and ex vivo evaluation of L-type calcium channel blockers on acid beta-glucosidase in Gaucher disease mouse models.
by: Ying Sun, et al.
Published: (2009-10-01)

Low Dose Lead and CNS Deficits
by: J Gordon Millichap
Published: (1990-01-01)

Impact of intracerebroventricular enzyme replacement therapy in patients with neuronopathic mucopolysaccharidosis type II
by: Joo-Hyun Seo, et al.
Published: (2021-06-01)

Characterization of Fluid Biomarkers Reveals Lysosome Dysfunction and Neurodegeneration in Neuronopathic MPS II Patients
by: Akhil Bhalla, et al.
Published: (2020-07-01)